THC, the primary psychoactive compound in cannabis, has several documented therapeutic effects that have led to FDA-approved medications for specific conditions. Its benefits are most established for chemotherapy-related nausea, muscle spasticity in multiple sclerosis, and appetite loss in serious illness. Beyond those, emerging evidence points to potential roles in pain management, sleep, and PTSD symptoms, though the strength of evidence varies considerably by condition.
How THC Works in the Body
THC produces its effects by binding to cannabinoid receptors, primarily CB1 and CB2, which belong to a larger signaling network called the endocannabinoid system. Your body naturally produces its own cannabinoid-like molecules that use this same system to regulate pain, mood, appetite, and inflammation. THC essentially mimics these natural molecules, but with stronger and longer-lasting effects.
CB1 receptors are concentrated in the brain and nervous system, which is why THC affects mood, perception, appetite, and pain processing. CB2 receptors are found mainly in immune cells and play a role in inflammation. When THC activates CB1 receptors, it alters how nerve cells communicate by changing calcium and potassium flow across cell membranes, ultimately reducing the release of certain chemical messengers. This broad mechanism explains why THC has such wide-ranging effects throughout the body.
Nausea From Chemotherapy
This is one of the best-supported uses of THC and the basis for two FDA-approved synthetic THC medications: Marinol (dronabinol) and Cesamet (nabilone). Both are specifically indicated for nausea associated with cancer chemotherapy, particularly when standard anti-nausea drugs haven’t worked. The American Society of Clinical Oncology recommends these medications for chemotherapy-induced nausea that doesn’t respond to conventional treatments.
A trial combining THC and CBD in patients already receiving standard anti-nausea treatment found that adding the cannabinoid combination nearly doubled the rate of complete nausea and vomiting control, from 14% to 25%. Patients who received the THC:CBD combination also reported significantly lower average nausea scores (2.1 versus 3 on a standardized scale) compared to placebo. These aren’t dramatic cure rates, but for patients who are still suffering despite conventional anti-nausea drugs, the improvement can be meaningful.
Appetite Stimulation in Wasting Conditions
The FDA has also approved dronabinol (Marinol and Syndros) for treating appetite loss and weight loss associated with AIDS. Anyone who has used cannabis recreationally is familiar with the appetite-stimulating effects, and this property has clinical relevance for people with serious illness who struggle to eat enough.
That said, the evidence for actual weight gain is weaker than many people assume. A systematic review and meta-analysis examining cannabis-based medicines for cachexia (severe wasting from chronic illness) found no statistically significant difference in weight change between cannabinoid treatment and placebo. The pooled data showed no meaningful weight improvement across the studies analyzed. So while THC reliably increases the desire to eat, translating that into measurable weight recovery in seriously ill patients has proven harder to demonstrate in controlled trials.
Muscle Spasticity in Multiple Sclerosis
One of the more robust areas of evidence involves THC-containing treatments for muscle stiffness and spasms in people with multiple sclerosis. The most commonly studied product is nabiximols, an oral spray containing both THC and CBD. A 2024 meta-analysis found that cannabinoid treatment significantly reduced spasticity scores on both patient-reported and clinician-measured scales. One large observational study reported roughly a 40% reduction in patient-rated spasticity scores after treatment with nabiximols.
For people with MS, spasticity is not just uncomfortable. It interferes with movement, sleep, and daily function. The reduction in spasticity scores seen in these studies reflects a real improvement in quality of life, and research on nabiximols has also shown improvements in upper limb function. While nabiximols is approved for MS spasticity in many countries, it has not yet received FDA approval in the United States.
Chronic Pain
Pain relief is probably the most commonly cited reason people use THC medicinally, and it’s where the gap between public perception and clinical evidence is widest. A Cochrane-level review of cannabis-based medicines for chronic neuropathic pain, published in 2025, found no clear evidence that THC-dominant medicines achieved meaningful pain relief. Specifically, the difference between THC and placebo for achieving at least 50% pain reduction was not statistically significant across seven studies involving over 500 participants. The same was true for the more modest threshold of 30% pain relief.
This doesn’t mean THC has zero effect on pain. Many patients report subjective improvement, and some of the benefit may come from THC’s ability to change the emotional experience of pain rather than the pain intensity itself. It may also help indirectly by improving sleep or reducing anxiety. But the controlled trial data for neuropathic pain specifically does not support THC as a reliable analgesic on its own.
PTSD and Nightmare Reduction
People with PTSD tend to have lower levels of their own natural cannabinoids, which contributes to the overactive fear responses and hyperarousal that characterize the condition. This biological rationale has led researchers to investigate whether supplementing with THC could help fill that gap.
A small study of 10 patients found that 5 mg of THC taken twice daily as an add-on to existing treatment improved sleep quality, reduced nightmare frequency, and decreased hyperarousal symptoms. Nabilone, the synthetic THC analogue, has shown similar benefits for nightmares and sleep disruption in PTSD patients. These findings are promising but based on very small samples, and the evidence is not yet strong enough to establish THC as a standard PTSD treatment.
Sleep and Insomnia
THC’s effects on sleep follow a pattern that depends heavily on how often you use it. In the short term, THC reduces the time it takes to fall asleep and decreases the number of times you wake up during the night. It also appears to increase slow-wave sleep, the deep restorative phase associated with physical recovery and memory consolidation. Early research suggested THC suppresses REM sleep (the dreaming phase), which is partly why it reduces nightmares. However, more recent studies using lower, therapeutic doses have reported mixed or no evidence of REM suppression.
The picture changes with regular use. Chronic users can develop tolerance to these acute sleep benefits, potentially leading to longer sleep onset times and less deep sleep over time. Stopping after regular use consistently causes rebound sleep problems: shorter total sleep, longer time to fall asleep, and increased REM activity. This withdrawal effect can make it difficult for regular users to sleep without THC, creating a cycle of dependence for sleep.
Glaucoma and Eye Pressure
THC lowers pressure inside the eye by about 25 to 30%, a finding first reported in the early 1970s. For a condition like glaucoma, where elevated eye pressure gradually damages the optic nerve, this sounds significant. The problem is duration: the pressure-lowering effect lasts only about three to four hours after smoking, meaning someone would need to use THC six to eight times daily to maintain the benefit. Modern glaucoma medications provide 24-hour pressure control with a single daily dose, making them far more practical. For this reason, major ophthalmology organizations do not recommend THC as a glaucoma treatment despite its measurable effect on eye pressure.
The Biphasic Effect
One of the most important things to understand about THC is that its effects are dose-dependent and often biphasic, meaning low and high doses can produce opposite results. This is most clearly seen with anxiety: low doses tend to be calming, while higher doses can trigger or worsen anxiety and paranoia. Similar patterns have been observed for pain and sleep. A scoping review confirmed that these biphasic effects exist across multiple symptom domains, though the exact doses at which the switch happens vary by individual and aren’t well defined in the research.
This means that “more THC” does not equal “more benefit.” For most therapeutic applications, the effective range appears to be at the lower end of dosing. People who use THC for health reasons and find it stops working or starts causing side effects may be experiencing this biphasic curve rather than a failure of the treatment itself.